T CELL VACCINATION: CLINICAL TRIAL FOR SECONDARY MS
$0M01FY2000RRNIH
University Of Southern California, Los Angeles CA
Investigators
Linked publications & trials
Paper 38278947Paper 38190104Paper 37902424Paper 37292813Paper 35291207Paper 34320286Paper 34161608Paper 33479058Paper 33071178Paper 32564066Paper 32064729Paper 31886931Paper 31685489Paper 31594431Paper 31559418Paper 31418516Paper 31338998Paper 31279092Paper 31167889Paper 31131339Paper 31118516Paper 31112370Paper 30997482Paper 30967435Paper 30916797Paper 30900413Paper 30833373Paper 30801985Paper 30734524Paper 30661481Paper 29936086Paper 29896938Paper 29758564Paper 29697830Paper 29614631Paper 29427697Paper 29398050Paper 29246363Paper 29157731Paper 28938457Paper 28865061Paper 28664624Paper 28378429Paper 28351939Paper 27803118Paper 27585671Paper 27161901Paper 27057209Paper 26888364Paper 26885808Paper 26868440Paper 26738099Paper 26628417Paper 26606887Paper 26577415Paper 26537182Paper 26531295Paper 26475177Paper 26362045Paper 26340467Paper 26339570Paper 26219302Paper 26181173Paper 26177958Paper 26046253Paper 26036801Paper 25950206Paper 25853639Paper 25784663Paper 25702853Paper 25690268Paper 25677718Paper 25488617Paper 25404660Paper 25392748Paper 25336561Paper 25197163Paper 25109932Paper 25064711Paper 24992554Paper 24987057Paper 24948348Paper 24898336Paper 24840081Paper 24830985Paper 24829202Paper 24819865Paper 24728128Paper 24650840Paper 24450390Paper 24433565Paper 24284880Paper 24204956Paper 24124113Paper 24123545Paper 24123261Paper 24062330Paper 24054930Paper 24030258Paper 24030069
Abstract
To determine if autologous peripheral T lymphocytes reactive to myelin proteins when injected back into the patient will stop the progression of hte disease. This is a Phase II randomized double-blind study of 80 patients (40x2). The primary outcome is MRI and secondary outcome mearurements are clinical and immunologivcal. This is a three-year study with two years of vaccination and one year follow-up.
View original record on NIH RePORTER →